RVLPQ — RVL Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $38.61m
- $49.72m
RVL Pharmaceuticals PLC expected to post a loss of 16 cents a share - Earnings Preview
Brief: Rvl Pharmaceuticals PLC Files For Mixed Shelf Of Up To $200 Million
Brief: Rvl Pharmaceuticals Plc Announces Preliminary Q4 Sequential Growth Of 21%
RVL Pharmaceuticals PLC reports results for the quarter ended in September - Earnings Summary
Brief: Rvl Pharmaceuticals PLC Reports Third Quarter 2022 Financial Results Provides Commercial Update
RVL Pharmaceuticals PLC expected to post a loss of 16 cents a share - Earnings Preview
Brief: Revision Skincare Announces Partnership With RVL Pharmaceuticals
Brief: RVL Pharmaceuticals Files Prospectus Relates To Resale/Other Disposition From Time To Time Of Up To 15.5 Million Ordinary Shares By Selling Shareholders
RVL Pharmaceuticals PLC reports results for the quarter ended in June - Earnings Summary
Brief: RVL Pharmaceuticals reports Q2 results
RVL Pharmaceuticals PLC expected to post a loss of 21 cents a share - Earnings Preview
Brief: Rvl Pharmaceuticals PLC Announces Insider And Athyrium-Led Financing
Brief: Rvl Pharmaceuticals PLC Announces Preliminary Second Quarter 2022 Upneeq® Net Product Sales Results
Reaffirms Q4 2022 Upneeq Net Product Sales Guidance Of $20 To $25 Mln
Brief: RVL Pharmaceuticals PLC Reports First Quarter 2022 Financial Results Provides Commercial Update
RVL Pharmaceuticals PLC expected to post a loss of 21 cents a share - Earnings Preview
RVL Pharmaceuticals PLC reports results for the quarter ended in December - Earnings Summary
RVL Pharmaceuticals PLC expected to post a loss of 27 cents a share - Earnings Preview
Osmotica up after brokerage starts coverage with 'buy'